Jang Il Moon
Yonsei University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Jang Il Moon.
Transplantation | 1998
Kiil Park; Jang Il Moon; Soon Il Kim; Yu Seun Kim
The donor organ shortage has been one of the major barriers to kidney transplantation in Korea, even though there has been a small but steady flow of cadaveric kidney donations for the last decade. To expand the donor pool in kidney transplantation, we have developed the exchange donor program at our institution and in Korea. The donor exchange program was first started for end-stage renal disease patients who had willing but incompatible related donors due to positive lymphocyte cross-match. The kidney transplantations were performed using exchanged kidneys between two families with successful results. Since this success, we have expanded the donor pool by accepting close relatives, spouses, friends of recipients, and willing voluntary donors as candidates for exchange donors with careful donor screening procedures. It helps relieve stress on donor supply. Particularly in those countries where brain death has not been socially or legally accepted, living donors including related, unrelated, and exchange donors should be considered as potential donors for kidney transplantation to relieve the pressure on donor organ shortage.
The Lancet | 2001
Yu Seun Kim; Jang Il Moon; Dong Kee Kim; Soon Il Kim; Kiil Park
Reduced renal mass or mismatching kidney size are risk factors for chronic allograft nephropathy. We assessed the effect of mismatching donor kidney weight and recipient bodyweight on renal graft function in 82 live donor kidney transplant recipients who did not have acute rejection. We calculated the donor kidney weight to recipient bodyweight ratio, and established the relation between this ratio and renal indices with a mixed model regression. We showed that recipients with a high ratio had better graft function.
Transplantation | 2001
Yu Seun Kim; Jang Il Moon; Hyeon Joo Jeong; Myoung Soo Kim; Soon Il Kim; Kyu Hun Choi; Ho Yung Lee; Dae Suk Han; Kiil Park
Background. The purpose of this study was to attempt to resolve two important issues, i.e. to determine (1) whether the course of recurrent immunoglobulin A nephropathy (IgAN) is benign, and (2) whether it is advisable to use a related donor. Methods. We evaluated the long-term outcome, in terms of recurrence and graft survival, after live related or unrelated donor renal transplantation, and assessed the validity of the use of related donors in 90 grafts in 89 IgAN patients. Results. Ten-year graft survival for IgAN patients was 66%, compared with 84% for 107 reference recipients who had other kinds of glomerulonephritis (GN), and with 69% in 90 other recipients who had non-GN renal failure (P =0.27). In 43 grafts, 54 event graft biopsies were performed, documenting the presence of mesangial IgA deposits in 19 of those grafts. In eight grafts, lesions were accompanied by chronic rejection (CR). Ten-year cumulative recurrence was 44%. Ten grafts were lost: by CR (n=3) or acute rejection (n=1) in 24 recurrence-free recipients, by CR (n=2) or recurrence (n=2) in 19 recurrent patients, and by patient death (n=2) in 46 patients devoid of graft biopsy. We found no difference in 10-year graft survival between the recurrent and recurrence-free patients (63% vs. 74%, P =0.98), or the proportion of related donors (68% vs. 83%, P =0.25). The presence or matching of HLA B12, B35, or DR4 did not affect the recurrence. Conclusions. Recurrence increased to 44% with longer follow-up, but this did not limit the graft outcome. Recurrence was not affected by the kind of live donor. We conclude that live related or unrelated kidneys should be offered to IgAN patients.
Surgical Endoscopy and Other Interventional Techniques | 2006
Tomoaki Kato; Jeffrey J. Gaynor; Seigo Nishida; Naveen K Mittal; Gennaro Selvaggi; David Levi; Jang Il Moon; John F. Thompson; Phillip Ruiz; Juan Madariaga; Andreas G. Tzakis
BackgroundThe small bowel has been successfully transplanted in patients with irreversible intestinal failure. This report aims to describe endoscopic monitoring of small bowel rejection.MethodsA magnification endoscope (zoom endoscope) was used in this study. In the first part of the study (October 1998 to March 2000, 271 endoscopy sessions), the specific endoscopic findings that correlated with rejection were determined. An analysis then was performed on data from the second period (March 2001 to November 2002, 499 sessions) to evaluate the zoom endoscope’s accuracy in monitoring rejection.ResultsSpecific endoscopic findings of rejection found in the first period included background erythema, villous congestion, blunted villous tip, and shortened villous height. When the rejection was successfully treated, endoscopic appearance returned to normal. On the basis of these findings, five endoscopic criteria (villous shortening, villous blunting, background erythema, villous congestion, and mucosal friability) were used to score endoscopic sessions in the second period. Endoscopic diagnosis of rejection was compared with histology. Adult patients showed a sensitivity of 45%, a specificity of 98%, a positive predictive value of 82%, and a negative predictive value of 88%. In pediatric patients, these values were, respectively, 61%, 84%, 57%, and 86%. On 59 distinct occasions (30 in period 1 and 29 in period 2) in which the results were endoscopy negative yet biopsy positive (mild) for rejection, we elected not to treat these rejections on the basis of clinical evaluation, and 58 (98%) resolved without further therapy.ConclusionsWith the use of magnification, endoscopy is a useful tool for monitoring acute rejection in the small bowel allograft.
Transplantation | 2005
Hee Chul Yu; Sony Tuteja; Jang Il Moon; Gary Kleiner; Lobella Conanan; Jeffrey J. Gaynor; Tomoaki Kato; David Levi; Seigo Nishida; Gennaro Selvaggi; C. Gandia; Debbie Weppler; Violet Esquenazi; Phillip Ruiz; Joshua Miller; Andreas G. Tzakis
Background. Citrulline concentrations have been proposed as a marker for intestinal allograft rejection. We instituted dried blood spot (DBS) specimen monitoring of citrulline to simplify sample collection posttransplant. This study demonstrates the correlation between plasma and dried blood spot specimen citrulline concentrations after intestinal transplantation. Methods. Plasma and DBS samples were analyzed by hydrophilic interaction chromatography tandem mass spectrometry. Comparison of the strength of linear correlation was made according to the type of surgery, sonication time, DBS citrulline levels, and the time interval between the blood sample collection and the assay date. Results. A very strong linear correlation exists between the plasma and DBS citrulline concentrations (r2=0.87; P<0.001). The correlation between plasma and DBS citrulline concentrations was maintained when evaluating only the intestinal transplant recipients. There was no significant difference in the strength of linear correlation according to sonication time, cirtrulline concentrations, or length of time to assay date. Conclusions. DBS citrulline monitoring will ease sample collection following intestinal transplantation and improve the ability to detect intestinal dysfunction and rejection by a noninvasive means.
Transplantation | 1999
Yu Seun Kim; Jang Il Moon; Soon Il Kim; Kiil Park
BACKGROUND According to a pooled analysis of three randomized clinical studies concerning the prevention of acute rejection in cadaveric renal transplantation, mycophenolate mofetil (MMF) proved superior to azathioprine or placebo in conjunction with cyclosporine (CsA) and steroids. MMF-treated patients showed reduced incidence and severity of acute rejection, similar graft survival, and better graft function over 12 months. However, the multicenter trials did not include the Asian recipients of living donor kidneys. METHODS To assess the efficacy of MMF as the third component of a triple therapy in addition to CsA-Neoral and steroids in living donor renal transplantation recipients in Asians, a total of 100 recipients were randomized to receive CsA-Neoral and steroids (control group, n=50), or MMF-based triple therapy (1.0 g of MMF twice daily from postoperative day 2, MMF group, n=50). The dosing plan for Neoral and steroids was essentially same between groups. During 12 months of follow-up, we compared the incidence of acute rejection, adverse events such as infections, and 12-month actual graft and patient survival. RESULTS The graft and patient survival at 1 year was excellent in both groups: 96/98% in the control group and 98/100% in the MMF group, respectively. MMF significantly reduced the proportion of patients with at least one episode of acute rejection (34% in the control group vs. 14% in the MMF group), cumulative incidence of acute rejection episodes (46% vs. 16%), and requirement of antilymphocyte antibody (21.7% vs. 12.5%). In the MMF group, viral infection such as herpes zoster or chicken pox was more prevalent than in the control group. CONCLUSIONS Like cadaveric renal transplantation, this open clinical trial showed MMF to be effective in reducing the incidence and severity of acute rejection if used in conjunction with Neoral and steroids after living donor renal transplantation in Asian ethnicity.
Surgery Today | 2001
Jang Il Moon; Yu Seun Kim; Sang Young Chung; Myoung Soo Kim; Soon Il Kim; Kiil Park
Abstract Long-term data on HLA-identical renal transplants are scarce, and the advantages of using cyclosporine (CsA) over azathioprine (AZA) have yet to be elucidated. In 68 recipients from HLA-identical donors (37 under AZA-steroids and 31 under CsA-steroids), we estimated the graft and patient survival to posttransplant 120 months, and compared the results between patients on different protocols. Episodes of rejection, causes of graft loss or patient death, and long-term complications were also compared retrospectively. The 10-year patient/graft survivals were comparable: 82.7/67.6% for the AZA and 78.4/63.5% for the CsA patients. The incidence of acute rejection during the first year after transplant was also comparable. We lost 25 grafts. The major causes of graft loss were patient death (7/13 in AZA and 5/12 in CsA patients) and chronic rejection (3/13 in AZA and 3/12 in CsA patients). Four grafts were lost due to poor compliance. We lost 12 patients due mostly to cerebrovascular disease and infections. There was no difference in the prevalence of complications between patients. In conclusion, the long-term outcome was excellent in this subgroup of transplant patients. We could not find any advantages of using CsA over AZA in these patients after a long-term follow-up. To achieve better results, continued attention should be paid to the prevention of poor compliance and complications.
Virchows Archiv | 2000
Hyeon Joo Jeong; Sun Hee Sung; Soon Won Hong; Jang Il Moon; Soon Il Kim; Yu Seun Kim; Kiil Park
Abstract The distribution pattern of extracellular matrix (ECM) components in transplant glomerulopathy was studied in relation to light microscopic features, actin expression of mesangial cells, and intraglomerular inflammatory cells. Nine cases of mild (group I) and nine cases of severe (group II) transplant glomerulopathy were stained with antisera against fibronectin (FN), tenascin (TN), collagen types III and IV, smooth muscle actin, CD45RO, CD68, and Ki-67 antigen. The composition of ECM was similar in the two groups. The expanded mesangium was diffusely stained by type-IV collagen, FN and TN, and focally and weakly stained by type-III collagen and smooth muscle actin. Type-IV collagen was linearly stained along the capillary walls, imparting a double-contour feature, whereas FN and TN showed granular staining along the capillary walls. CD68 positive cells were increased in severe transplant glomerulopathy, but this increase was not related to ECM deposition. These findings suggest that increased glomerular deposition of normal and abnormal ECM components participate in the evolution of transplant glomerulopathy.
Surgical Endoscopy and Other Interventional Techniques | 2002
Noriyo Yamashiki; Tomoaki Kato; R. W. Bailey; Akin Tekin; Jang Il Moon; David Levi; K.R Reddy; Eugene R. Schiff; Andreas G. Tzakis
Microwave coagulation therapy has been used for local ablation of hepatocellular carcinoma in the setting of liver cirrhosis. This technique can be performed laparoscopically when the tumor is located on the surface of the liver or attached to other intraabdominal organs. However, a laparoscopic approach becomes difficult when it is necessary to mobilize the liver or lyse adhesions to gain access to the tumor. We used a hand-assisted laparoscopic technique for the applicafion of microwave coagulation therapy in two cirrhotic patients with hepatocellular carcinoma to ensure safe mobilization of the liver and adhesiolysis. The first patient presented with a 4.5-cm mass in the left lobe of the liver that was densely adherent to the lesser omentum. The use of a hand-assist device allowed us to perform a safe exptoration, adhesiolysis, and subsequent tumor ablation. In the second patient, the tumor was located on the posterior aspect of the right lobe of the liver. The handassist device allowed safe mobilization of the liver and exposure of the tumor. No significant postoperative complications were noted in either patient. Complete ablation of the tumors was confirmed with contrastenhanced computed tomography scanning. In conclusion, hand-assisted iaparoscopy is an effective adjunct to microwave ablation therapy in patients with hepatocellular carcinoma and liver cirrhosis. It enables the safe completion of the procedure under laparoscopic guidance, thereby averting laparotomy.
Transplantation Proceedings | 1999
Kyu-Sang Park; Jang Il Moon; Sunok Kim; Yung-soo Kim